Alexion Pharma (ALXN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BMO Capital Upgrades Alexion Pharmaceuticals (ALXN) to Outperform
April 29, 2016 6:35 AM EDTBMO Capital upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Market Perform to Outperform with a price target of $168.00 (from $165.00).
Analyst M. Ian Somaiya commented, "We believe a sell-off in ALXN post 1Q16 earnings provides an ideal entry point ahead of two major clinical... More
